Due to health issues, this site is no longer maintained and will be shut down shortly.

LN:HCM Hutchison China MediTech Limited

Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company provides drug research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. It also develops clinical drug candidates, including AZD6094 that is in Phase II clinical trial for treating non-small cell lung, colorectal, and gastric cancer; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib, a Phase II clinical trial product for neuroendocrine tumors and thyroid cancers; and Epitinib for the treatment of non-small cell lung cancer that is in Phase Ib clinical trial. In addition, the company is developing Theliatinib, a Phase I clinical trial product for the treatment of solid tumors; HMPL-523, a Phase I clinical trial product for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a Phase I clinical trial product for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453 that is in Phase I clinical trial for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is based in Central, Hong Kong. Hutchison China MediTech Limited operates as a subsidiary of Hutchison Healthcare Holdings Limited.This company has ADRs that trade in the U.S. as the symbol HCM.

232.50 GBP
As of 03/08/2023

Security Information
Category1:  Global Equity
Category2:  Common stocks
Category3:  Emerging markets
GICS sector:  Health Care
Industry:  Drug Manufacturers-Specialty &
Index country:  Hong Kong
Country of incorporation:  Cayman Islands
IPO date:  05/19/2006
Stock exchange:    London Stock Exchange
Exchange country:   United Kingdom
Market cap:   1,314,087,168 GBP
Current dividend yield:   0.00%
Sedol:      B11Y2X4

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy